Nuvation Bio Secures FDA Priority Review for Taletrectinib Nuvation Bio's leading cancer drug, taletrectinib, has been granted FDA Priority Review for advanced ROS1-positive NSCLC, with a PDUFA date set for June 23, 2025. The company is also advancing commercialization efforts globally, including approvals in China and a pending application in Japan.123